Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502867-39-00

Acronym

20220073

Enrollment

Registered

2023-08-23

Start date

2023-09-29

Completion date

2025-12-12

Last updated

2025-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced solid tumors including non-small cell lung cancer (NSCLC), cervical carcinoma, head and neck carcinoma, mesothelioma, ovarian cancer, pancreatic adenocarcinoma, uterine carcinoma and breast cancer.

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

France, Germany, Spain

Outcome results